Clinical trials: Treatment As Usual
Schizophrenia
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered…
- Trial name
- PROSIPAL (NCT01081769)
- Testing
- paliperidone palmitate injection, oral antipsychotics
- Where
- 94 sites in Austria, Belgium and 23 more
- Volunteers
- 769 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics
The goal of this project is to show that the best possible option for preventing relapses in patients suffering from first episode (<1 year of anti-psychotic medication) or early phase (< 5 years of lifetime exposure to…
- Trial name
- PRELAPSE (NCT02360319)
- Testing
- Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
- Where
- 39 sites in United States
- Volunteers
- 489 people
- Sponsor
- Vanguard Research Group
Smoking Cessation
A Multi-National Study To Assess How Effective And Safe The Smoking Cessation Medicine Varenicline Is In Smokers Who Have Already Tried Varenicline In The Past As A Prescription Medicine From Their Usual Healthcare Provider
The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment.
- Trial name
- NCT01244061
- Testing
- Varenicline
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 498 people
- Sponsor
- Pfizer
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 mcg and 5 mcg once daily) over 12 weeks, compared to placebo, as add-on controller therapy…
- Trial name
- NCT01277523
- Testing
- tiotropium high dose, tiotropium low dose
- Where
- 69 sites in United States, Argentina and 12 more
- Volunteers
- 392 people
- Sponsor
- Boehringer Ingelheim
Stress Disorders, Post-Traumatic
Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: CCT, TF-CBT, TAU
This study is designed to examine three treatment conditions for traumatized youth: Cue-Centered Treatment (CCT), Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT), and Treatment as Usual (TAU) to determine which treatment…
- Trial name
- NCT02926677
- Testing
- Cue-Centered Treatment (CCT), Trauma-Focused CBT (TF-CBT), Treatment as Usual
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Stanford University
Computer + Fluency, Computer Only
Evaluation of a Computerized Opioid Overdose Prevention Program
Unintentional fatal drug overdose (OD) is now the 2nd leading cause of accidental death in the general population. Fatal OD from opioid analgesics specifically has increased over 400% between 1999 and 2008, and nonfatal overdose…
- Conditions
- Computer + Fluency, Computer Only, Treatment as Usual
- Trial name
- NCT02040077
- Testing
- Computer + Fluency, Computer Only, Treatment as Usual
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT05276973
- Testing
- Biopsy Procedure, Carboplatin, Ipatasertib
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Schizophrenia
CAE for Poorly Adherent Individuals With Schizophrenia
This project aims to evaluate the feasibility, acceptability and preliminary efficacy of remotely delivered CAE among patients with schizophrenia (CAE-S).
- Trial name
- CAE-S (NCT06061952)
- Testing
- Customized Adherence Enhancement for Schizophrenia (CAE-S), Enhanced Treatment as Usual (eTAU)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University Hospitals Cleveland Medical Center
Modified DECIDE Intervention, Treatment as Usual Care Group
The DECIDE Parent-Provider Intervention
The DECIDE Parent-Provider Intervention is designed to support parents caring for adolescents who are receiving treatment for Disruptive, Impulse-Control, and Conduct disorders.
- Trial name
- NCT04445155
- Testing
- Modified DECIDE Parent and Provider Intervention
- Where
- 5 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia, Dual Diagnosis
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
Many individuals with schizophrenia also suffer from marijuana addiction. Clozapine, an atypical antipsychotic medication, may prove useful at preventing drug relapse in schizophrenic individuals who are seeking treatment for…
- Conditions
- Schizophrenia, Dual Diagnosis, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00498550
- Testing
- Clozapine, Treatment as usual
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Postpartum Depression
[Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]
This study evaluates the efficacy of two digital therapeutics, WB001 and ED001, on depressive symptoms among women diagnosed with postpartum depression.
- Trial name
- NCT05551195
- Testing
- WB001, ED001
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Woebot Health
Mother-infant Relational Disturbances
Mother-Infant Psychoanalysis Project of Stockholm
Mother-infant relationship disturbances broadly comprise three areas; maternal distress, infant functional problems, and relationship difficulties.
- Trial name
- MIPPS (NCT00923559)
- Testing
- Treatment as Usual at Child Health Centre, Mother-Infant Psychoanalytic treatment (MIP)
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Karolinska Institutet
Opioid Use Disorder
TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment…
- Trial name
- NCT02730403
- Testing
- Treatment As Usual
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- NYU Langone Health
Schizophrenia
L-arginine in Treatment as Usual in Schizophrenia
STUDY OBJECTIVES: To determine whether the addition of L-arginine to treatment as usual (TAU) in schizophrenia further improves and enhances therapeutic efficacy (positive, negative and depressive symptoms) and effectiveness of…
- Trial name
- NCT00718510
- Testing
- L-Arginine
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- University of Alberta
Major Depressive Disorder
Automatic Self Transcending Meditation Versus Treatment as Usual
Depression is a leading contributor to global burden of disease. Antidepressants do not provide adequate response for many patients.
- Trial name
- NCT02149810
- Testing
- Automatic Self Transcending Meditation
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on…
- Trial name
- NCT01634152
- Testing
- Tiotropium low dose mcg, Tiotropium high dose
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00776984
- Testing
- tiotropium 5mcg/day
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 453 people
- Sponsor
- Boehringer Ingelheim
Suicide, Suicidal Ideation
Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations
The purpose of the proposed study is to identify the most effective brief interventions for reducing short-term risk for suicide attempts in "real world" military triage settings, and to identify potential mechanisms of change…
- Trial name
- BISSR (NCT02042131)
- Testing
- Treatment As Usual (TAU), Standard Crisis Response Plan (S-CRP), Enhanced Crisis Response Plan (E-CRP)
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of Utah
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00772538
- Testing
- tiotropium 5mcg/day
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Boehringer Ingelheim